Summary: Several pediatric Hodgkin lymphoma (HL) consortia have demonstrated safe omission of radiotherapy (RT) in early stage HL, whereas feasibility of omitting RT in advanced HL is still under investigation. This is a single institution retrospective analysis of 27 patients with intermediate-risk or high-risk HL (age 22 y and younger), treated with a modification of the dose-intensive OEPA-COPDAC (vincristine, etoposide, prednisone, doxorubicincyclophosphamide, vincristine, prednisone, dacarbazine) regimen, with radiation restricted to only sites of inadequate early response (Deauville ≥ 3 and/or ≤ 75% tumor shrinkage). Their outcome was compared with a historical cohort (n = 42) treated with Stanford V or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), who received consolidative involved-field RT. RT was omitted in 15 of 27 (56%) of patients treated with OEPA-COPDAC, majority of whom (67%) had high-risk disease. At a median follow-up of 3.1 years, the 3-year progression-free survival was 100% in patients who received OEPA-COPDAC, versus 83.3% (95% confidence interval, 68.2%-91.7%) in the historical cohort, P = 0.03. Our analysis demonstrates excellent survival with omission of RT in more than 50% of patients with pediatric advanced HL, treated with a dose-intensive chemotherapy regimen. When administered, RT was restricted to only sites of inadequate early response. Results of large prospective studies are needed to validate these findings.
H odgkin lymphoma (HL) in children and adolescents is highly curable and long-term survival exceeds 95% with combination of chemotherapy and radiation therapy (RT). 1 However treatment-related sequelae significantly contribute to morbidity among survivors. 2 Consequently, efforts have focused on optimizing therapy while maintaining excellent cure rates, through risk-based and response-based strategies. 3 Such efforts include decreasing RT dose and field, and when possible, eliminating RT in patients who have a favorable early response.
Several pediatric consortia have demonstrated responsebased omission of radiation in patients who have low-risk disease, without any significant impact on event-free survival (EFS). The Pediatric Hodgkin Lymphoma Consortium (PHLC) which includes St. Jude Children's Research Hospital, Dana-Farber Cancer Institute, Lucile Packard's Children Hospital at Stanford, Massachusetts General Hospital, and Maine Medical Center, showed successful omission of RT in patients with early stage disease (stage IA, IIA, <3 nodal sites, nonbulky) who achieved a complete response (CR) (defined as ≥ 75% tumor reduction and negative gallium or positron emission tomography [PET] scan) after 2 cycles of VAMP (vincristine, doxorubicin, methotrexate and prednisone) chemotherapy. 4 Likewise, the German Society of Pediatric Oncology and Hematology-Hodgkin Lymphoma (GPOH-HD) 95 trial showed RT could be safely omitted in their lowest risk patients who were in CR after 2 cycles of OEPA (vincristine, etoposide, prednisone, and doxorubicin) or OPPA (vincristine, procarbazine, prednisone and doxorubicin) chemotherapy. 5 In the same trial, patients with advanced disease received 2 to 4 cycles of COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) or COPP (cyclophosphamide, vincristine, prednisone, procarbazine) chemotherapy, followed by radiation to all involved sites of disease. The successor GPOH-HD 2002 study further demonstrated that the procarbazine-free OEPA-COPDAC, and OPPA-COPP where equivalent regimens. The Children's Oncology Group in a large randomized phase III study in HL (AHOD0031), evaluated if RT could be omitted inpatients with intermediate-risk disease who were rapid early responders and in CR after 4 cycles of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide-prednisone, and cyclophosphamide). Their results showed no difference in 4-year EFS irrespective of administration of RT (87.9% in RT arm vs. 84.3% without RT). 6 However, the feasibility of eliminating RT in children and adolescents with high-risk HL is still under investigation and previous studies showed lower EFS in patients who did not receive radiation, although there was no impact in the overall survival (OS). 5, 7 Building on the experience of successive GPOH-HD trials, the European Pediatric and Adolescent Hodgkin Lymphoma Network (EuroNet-HD) undertook its first international cooperative trial (EuroNet-HD-PHL-C1) (NCT00433459), which evaluated the omission of RT in all patients (irrespective of disease stage) who had an adequate response to 2 cycles of OEPA. Unlike in prior GPOH-HD studies, response was defined by both an adequate 18-fluorodeoxyglucose PET (FDG-PET) scan, and volumetric reduction on computed tomography (CT). Patients who did not have an adequate early response received RT to all involved disease sites. Interim results of this study show elimination of RT in 48% of all patients enrolled with no decrement in EFS between irradiated and nonirradiated patients. 8 In 2011, the Dana-Farber/Boston Children's Cancer and Blood Disorders Center adopted the GPOH-HD derived OEPA-COPDAC chemotherapy backbone 5, 9 with slight modifications, as standard of care for patients not enrolled on a research study. Deviating from the EuroNet-HD C1 treatment plan, and modelled after concurrent PHLC research studies of the time, we also instituted a response-based paradigm of administering radiation to only the sites of inadequate early response. We report our single institution experience of this modified OEPA-COPDAC and response-based radiation elimination strategy, in children with intermediate-risk or high-risk disease. We also compare the outcomes of patients treated with our current standard of care, to a historical cohort treated with standard regimens and who all received involved-field RT (IFRT).
PATIENTS AND METHODS

Patient Identification
Following approval from the Institutional Review Board (IRB), we queried the department of pathology database at Boston Children's hospital for all patients younger than 22 years of age diagnosed with HL at our institution from January 1, 2005 through December 31, 2015. One hundred thirty-five patients were identified. Cases were selected for inclusion in our analysis if they were newly diagnosed with classical HL, received treatment in our institution and had Ann Arbor Stage IA E, IB E , IIA bulky (peripheral lymph node aggregate > 6 cm or mediastinal mass greater than one-third of the intrathoracic diameter), IIA E IIB, IIB E , IIIA, IIIB or Stage IV at diagnosis. Seventy patients met the inclusion criteria.
We identified 27 consecutive patients who were treated with our current standard of care (OEPA-COPDAC) with response-based omission of RT, and a historical cohort consisting of 43 subjects treated with either Stanford V regimen 10 or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and consolidative IFRT. One of the patients in the historical cohort who was treated in the recent years did not receive IFRT, and was excluded from the analysis. The remaining 69 subjects were included in this analysis (Fig. 1) . For this analysis, we risk stratified these 69 subjects into intermediate-risk (IA E, IB E, IIA bulky, IIA E , IIB, and IIIA) and high-risk (IIB E , IIIB, IVA, and IVB) disease.
Treatment
Twenty-seven subjects were treated with OEPA-COP-DAC regimen from 2011 to 2015. Table 1 compares our institutional adoption of the OEPA-COPDAC regimen with the EuroNet-HD treatment schema highlighting the minor differences in our risk group stratification and number of COPDAC cycles administered by risk group. The dosing and timing of chemotherapy was same as previously published. 9 All subjects first received 2 cycles of OEPA followed by 2 to 4 cycles of COPDAC. Patients with intermediate-risk disease received 2 to 4 cycles of COPDAC, while those with high-risk disease received 4 cycles of COPDAC. All the subjects underwent interval response assessment with FDG-PET and CT after the 2 cycles of OEPA. An adequate early response was defined as a negative FDG-PET (Deauville ≤ 3) and ≥ 75% tumor reduction based on the product of the perpendicular diameter on CT. Patients who had an adequate response after 2 OEPA cycles were offered omission of RT after risk/benefit discussions involving patients and their families, and both the pediatric and radiation oncologists. All patients with an inadequate response at the early response assessment received 25.5 Gy RT in 1. made to include entire nodal chain; however, the supraclavicular nodes were included with mediastinal nodal irradiation. Radiation was started within 2 to 4 weeks of completion of chemotherapy.
The 42 patients in the historical cohort were treated between 2005 and 2011. Thirty-one were treated with Stanford V regimen for 12 weeks, and the remainder 11 subjects received 6 cycles of ABVD. Of the patients treated with Stanford V, 25 were enrolled on existing PHLC research studies. All patients in this cohort received 15 to 25.5 Gy of IFRT in 1.5 Gy daily fractions.
Statistical Analysis
The primary end points were progression-free survival (PFS) and OS. PFS was defined as the time from diagnosis to progression or death from any cause and OS was defined as time from initial diagnosis to death from any cause. Survival distributions were examined using the KaplanMeier curves and the differences between groups analyzed using the log-rank test, while differences in the distribution of categorical variables were analyzed using the Fisher exact test or the χ 2 test and the t test for continuous variables, using a significant two-sided P-value <0·05. All statistical analyses were performed using Stata version 14.1 (StataCorp, College Station, TX). Table 2 . The median age of all 69 patients was 15.6 years (range: 4.7 to 21.2 y)-16 years in those treated with our current standard of care, versus 15.3 years in the historical cohort. Females constituted 51% of all the patients and nodular sclerosis was the predominant histologic subtype (80%). Eighteen of the 27 patients treated with OEPA-COPDAC (67%) had highrisk disease, versus 13 of the 42 patients (31%) in the historical cohort. (P = 0.004). Only 1 patient, who was from the historical cohort, had an E lesion (IIA E ). The distribution of bulky disease was similar between both cohorts-30% in OEPA-COPDAC and 31% in the historical cohort. There was no difference in the proportion of patients with B symptoms (44% vs. 43% in the historical cohort).
RESULTS
Patient characteristics are summarized in
Fifteen of the 27 patients (56%) treated with our current standard of care did not receive RT. This was equal for both intermediate-risk and high-risk disease. None of the patients who had an adequate early response received RT. In all cases, the patients and their families agreed with their treatment provider's recommendation to omit radiotherapy. Similarly, all patients with an inadequate early response after 2 cycles of OEPA received RT to the sites of inadequate response. Two early patients with intermediate-risk disease received 2 cycles of COPDAC; all others received 4 cycles of COPDAC. The median duration of follow-up for patients treated with OEPA-COPDAC was 3.1 years, compared with 6.3 years in the historical cohort. None of the patients treated with OEPA-COPDAC and our response-based approach has experienced disease progression or relapse to date. One patient progressed on treatment and 6 others relapsed in the historical cohort. Five of the 7 subjects who relapsed received Stanford V chemotherapy with cyclophosphamide instead of mechlorethamine when the latter agent was unavailable. The 3-year PFS for subjects treated using our response-based approach was 100% versus 83.3% (95% confidence interval, 68.2%-91.7%), P = 0.03 (Fig. 2 ) and 3-year OS of 97.6% (95% confidence interval, 84.2%-99.6%) in the historical cohort (Fig. 3) .
DISCUSSION
Utilizing early response assessment of FDG-PET and CT, we avoided RT in 56% of patients with intermediaterisk or high-risk HL treated with OEPA-COPDAC. We have not observed any treatment failures in this cohort at a median follow-up of 3 years. Given that we only recently adopted this treatment paradigm, the follow-up duration was shorter compared with our historical cohort who received RT and other standard chemotherapy regimens. Nevertheless, most of the treatment failure in the historical cohort occurred within 2 to 3 years of completion of therapy consistent with earlier pediatric HL studies. [5] [6] [7] In children with advanced disease, administering RT to all sites of disease involvement may lead to significant risk of late effects including cardiovascular disease and second malignancies, but more limited radiotherapy fields may partially mitigate this risk. 11, 12 To further limit exposure to normal tissues, we only irradiated sites of disease that had an inadequate response to 2 cycles of OEPA. Radiotherapy †Ann Arbor Stage IIB E IIIB, IVA, and IVB. ‡Adequate response (18-fluoro-deoxyglucose positron emission tomography Deauville ≤ 3+ ≥ 75% shrinkage in product of perpendicular diameter on computed tomography).
ABVD indicates adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine; NA, not available; NS, not statistically significant; OEPA-COPDAC, vincristine, etoposide, prednisone, adriamycin-cyclophosphamide, vincristine, prednisone, dacarbazine.
to involved node or involved site delivers considerably less radiation to normal tissues with the goal of decreasing toxicity, 13 as do techniques using deep inspiration breath hold, intensity modulated radiation therapy and proton beam. 14 Overall, the decision to withhold consolidative radiotherapy must be balanced by the recognition that some children may relapse, requiring more intensive chemotherapy and radiotherapy for salvage. Our institutional practice includes a multidisciplinary discussion with the patient and family, pediatric oncologist and radiation oncologist to review the recommendations, including the risks and benefits of giving or omitting radiation. In adults, the application of adjuvant RT in advanced HL is even more controversial, and several randomized trials have questioned its role. 12, [15] [16] [17] [18] The results of these trials appear to suggest a benefit in adult patients with advanced HL who have not achieved complete remission or who have residual disease after chemotherapy.
We adapted the EuroNet-HD backbone with some modifications. Our intermediate-risk stratum, unlike Treatment Group 2 (TG2) in the predecessor GPOH-HD studies, included patients with stage IIA bulky disease. Also, the EuroNet-HD did not exclude these patients from their most favorable group until a retrospective analysis of the C1 trial showed that patients in their lowest risk group (Treatment Group 1) who had bulky disease (volume ≥ 200 mL) or Erythrocyte Sedimentation Rate (ESR) ≥ 30 mm/h had poorer EFS. 8 These patients will now be assigned to the intermediaterisk group in the current EuroNet-PHL-C2 trial (NCT02684708). Furthermore, most of our patients with intermediate-risk disease, received 4 cycles of COPDAC instead of 2 cycles administered in the EuroNet-C1 trial and GPOH-HD studies. The TG2 patients in the GPOH-HD 95 study who did not receive IFRT had the lowest EFS (10-y EFS 68.5% vs. 91.4% if RT was administered, P < 0.001). 5 We speculated that 2 cycles of OEPA plus 2 cycles of COPDAC was not sufficient treatment in the absence of consolidative RT. As our goal was to minimize the use of radiotherapy, we administered 6 cycles of chemotherapy to most patients with intermediate-risk disease. Hence, it is it possible we may have "over-treated" some of these patients. However, OEPA-COPDAC is a well-tolerated regimen with both low cumulative dose of anthracyclines and alkylators as well as a minimal toxicity profile. 9 The 2 additional cycles of COPDAC administered to patients with intermediate-risk disease resulted in only a modest increase in the cumulative dose of cyclophosphamide from 2 to 4 g/m 2 without additional anthracycline exposure. This appeared to be an acceptable trade-off, to avoid the potential late effects of radiation.
Early interim FDG-PET has emerged as an important predictive and prognostic tool in HL therapy, particularly in adults. [19] [20] [21] However, FDG-PET is not well validated as a predictive tool in childhood HL and its optimal use with pediatric dose-intensive regimens is still under investigation. 3 Moreover, there is no consensus on what constitutes an adequate PET response, or the best time (in relation to cycles of therapy) to obtain interval disease assessments and there are questions around how best to incorporate it with CT measurements of tumor reduction. We used a Deauville score of ≤ 3 to delineate PET negative disease. In contrast, the EuroNet-C1 used the International Harmonization Project Criteria (IHP), with a negative PET being the equivalent of Deauville ≤ 2. 22, 23 Although widely accepted, the Deauville scoring method is subject to inter-reader variability, 24 and a quantitative PET methodology that extends the Deauville score to a continuous scale has been suggested. 25 In conclusion, although limited by the retrospective design and small number of patients, utilizing a responsebased paradigm, we omitted radiation in more than 50% of patients with intermediate-risk or high-risk HL treated with the dose-intensive OEPA-COPDAC regimen while maintaining an excellent survival. The standard practice in most pediatric centers is to administer IFRT in advanced HL, however we restricted RT to only the sites of inadequate early disease response. In our patients, we demonstrate that this strategy is feasible, but results of prospective studies are needed to validate our findings.
